ClinicalTrials.gg
CompletedNCT03019549Updated Nov 1, 2019Results posted

A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin

A Phase 1 interventional study of Lanabecestat and Rosuvastatin in Healthy, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-01.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any side effects that may occur will also be collected.

Participants will be on study for 21 days with a follow-up at least 7 days afterwards.

Screening will be undertaken within 45 days prior to enrollment.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women not of may participate and include those who are:

    • Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or
    • - defined as women over 50 years of age with an intact uterus who have not taken hormones or oral within 1 year, who have had either Spontaneous cessation of menses for at least 12 consecutive months, or 6 to 12 months of spontaneous amenorrhea with follicle-stimulating hormone level greater than (>)40 milli-international units per millilitre (mIU/mL) consistent with menopause
  • Caucasian and may be of Hispanic ethnicity
  • (BMI) of 19 to 32 kilogram per meter square (kg/m²), inclusive, at the time of screening

Exclusion criteria

Exclusion Criteria:

  • Have a abnormal blood pressure or heart rate (supine) as determined by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Rosuvastatin

    Period 1: 20 mg rosuvastatin administered once orally (PO)

    Drug: Rosuvastatin

  • Experimental
    Lanabecestat + Rosuvastatin

    Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8

    Drug: Lanabecestat · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin

    Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve from Zero to Infinity (AUC-∞) of Rosuvastatin

    Time frame: 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)

    Pharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)

    Time frame: Period 2 (Day 7, 8): Predose, 0.5, 1, 2, 3, 4, 8, 12 hours postdose

  2. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat

    Time frame: .Period 2 (Day 7, 8): Predose, 0.5, 1, 2, 3, 4, 8, 12 hours postdose

07

Results

Posted Apr 16, 2019
Limitations and caveats
11 participants completed Period 1 and then discontinued due to genotyping criteria.

Participant flow

Period 1
Participant flow — Period 1
MilestoneOverall Study
Started42
Received 1 dose of study drug42
Completed42
Not completed0
Washout
Participant flow — Washout
MilestoneOverall Study
Started42
Completed31
Not completed11
Withdrew: Did not meet genotype criteria11
Period 2
Participant flow — Period 2
MilestoneOverall Study
Started31
Received at least 1 dose of study drug29
Completed26
Not completed5
Withdrew: Adverse event2
Withdrew: Physician decision2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin

Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve from Zero to Infinity (AUC-∞) of Rosuvastatin

Time frame:
1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose
Reported as:
Geometric mean · hours times nanogram per milliliter
Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin
hours times nanogram per milliliterRosuvastatinRosuvastatin + Lanabecestat (LY3314814)
Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin80 ± 4778 ± 56
SecondaryPharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)

Pharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)

Time frame:
Period 2 (Day 7, 8): Predose, 0.5, 1, 2, 3, 4, 8, 12 hours postdose
Reported as:
Geometric mean · hours times nanograms per milliliter
Pharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)
hours times nanograms per milliliterLanabecestat (LY3314814)Rosuvastatin + Lanabecestat (LY3314814)
Pharmacokinetics (PK): Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat (LY3314814)3650 ± 253790 ± 21
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat

Time frame:
.Period 2 (Day 7, 8): Predose, 0.5, 1, 2, 3, 4, 8, 12 hours postdose
Reported as:
Geometric mean · nanograms per milliliter
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat
nanograms per milliliterLanabecestat (LY3314814)Rosuvastatin + Lanabecestat (LY3314814)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lanabecestat369 ± 27399 ± 20

Adverse events

Collected over Up to 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20 mg Rosuvastatin0/42 (0%)0/42 (0%)0/42 (0%)
50 mg Lanabecestat (LY3314814)0/29 (0%)0/29 (0%)2/29 (6.9%)
Lanabecestat (LY3314814) + 20 mg Rosuvastatin0/26 (0%)0/26 (0%)3/26 (11.5%)
Most frequent other events
Most frequent other events
Event20 mg Rosuvastatin50 mg Lanabecestat (LY3314814)Lanabecestat (LY3314814) + 20 mg Rosuvastatin
Dizziness posturalNervous system disorders0/420/293/26
Surgical skin tearInjury, poisoning and procedural complications0/422/290/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study
Mean45.2 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female20
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino16
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White42
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
United States42
Genotype rsl045642 (ABCB1)
Genotype rsl045642 (ABCB1)(Participants)Overall Study
Genotype A/A10
Genotype A/G15
Genotype G/G6
Not performed11
08

Study locations

1 site
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in May 2017, 4 months.

Results were first posted in Apr 2019, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2017
First posted
Jan 12, 2017
StartActual
Jan 12, 2017
Primary completionActual
May 22, 2017
CompletionActual
May 22, 2017
Results first posted
Apr 16, 2019
Last update
Nov 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03019549
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 12, 2017
Start date
Jan 12, 2017
Primary completion
May 22, 2017
Completion
May 22, 2017
Results posted
Apr 16, 2019
Last update
Nov 1, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lanabecestat · Rosuvastatin

Start the discussion